Effectiveness and Safety of Dexamethasone implants for post surgical macular oedema including Irvine-gass syndrome
Reviewed by Jonathan Chan

This is a retrospective, multicentre, uncontrolled, consecutive case series from Lyon, France between April 20111 to June 2014, with minimum of one year follow-up. The clinical features including the best corrected acuity (BCVA), central subfield macular thickness (CSMT) and intraocular pressure were measured before and after 0.7mg of the implants were injected to the patients. The mean BCVA was improved from 9.6 letters at six months to.10.3 letters at 12 months (p<0.001). The mean reduction of CSMT was 135.2um and 160.9um at six and 12 months respectively (p<0.001); 37% of patients did not need second injection. The presence of more than one PSMO risk factor decreases the probability of a gain of visual acuity >10 letters. Initial VA of <50 letters at baseline and non-naïve status are both factors that will decrease the probability of single injection during follow up. The authors concluded that naïve patients is a good prognostic factor and sustainable gain of BCVA was sustainable at six and 12 months follow up period. 

Effectiveness and safety of dexamethasone implants for postsurgicalmacular oedema including irvine-gass syndrome: the episodic-2 study.
Bellocq D, Pierre-Kahn V, Matonti F, et al.
BRITISH JOURNAL OF OPHTHALMOLOGY
2017;101:333-41.